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Background: Aberrant DNA methylation is frequently found in human malignancies including acute myeloid
leukemia (AML). While most studies focus on later disease stages, the onset of aberrant DNA methylation events
and their dynamics during leukemic progression are largely unknown.
Methods: We screened genome-wide for aberrant CpG island methylation in three disease stages of a murine AML
model that is driven by hypomorphic expression of the hematopoietic transcription factor PU.1. DNA methylation
levels of selected genes were correlated with methylation levels of CD34+ cells and lineage negative, CD127-, c-Kit+,
Sca-1+ cells; common myeloid progenitors; granulocyte-macrophage progenitors; and megakaryocyte-erythroid
progenitors.
Results: We identified 1,184 hypermethylated array probes covering 762 associated genes in the preleukemic
stage. During disease progression, the number of hypermethylated genes increased to 5,465 in the late leukemic
disease stage. Using publicly available data, we found a significant enrichment of PU.1 binding sites in the preleukemic
hypermethylated genes, suggesting that shortage of PU.1 makes PU.1 binding sites in the DNA accessible for aberrant
methylation. Many known AML associated genes such as RUNX1 and HIC1 were found among the preleukemic
hypermethylated genes. Nine novel hypermethylated genes, FZD5, FZD8, PRDM16, ROBO3, CXCL14, BCOR, ITPKA, HES6
and TAL1, the latter four being potential PU.1 targets, were confirmed to be hypermethylated in human normal
karyotype AML patients, underscoring the relevance of the mouse model for human AML.
Conclusions: Our study identified early aberrantly methylated genes as potential contributors to onset and
progression of AML.Background
Acute myeloid leukemia (AML) is an aggressive
hematopoietic malignancy associated with severe morbidity
and poor prognosis. It comprises a highly heterogeneous
group of blastic myeloid malignancies and constitutes the
most frequent type of acute leukemia in adults [1]. AML
can arise de novo but also secondarily from preceding mye-
lodysplastic syndrome (MDS), or after cytotoxic treatment
or radiotherapy. It is characterized by an aggressive clonal
proliferation of immature hematopoietic progenitor cells* Correspondence: c.plass@dkfz.de
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unless otherwise stated.(myeloblasts) and impaired differentiation [2]. Recurrent
chromosomal aberrations and rearrangements occur in
more than 50% of cases and represent important predictive
factors for response to therapy and outcome of the disease
[3]. Altered gene function in AML is often a consequence
of distinct cytogenetic aberrations [4], but also results from
mutations in genes like CEBPA (CCAAT/enhancer-binding
protein, alpha), FLT3 (fms-like tyrosine kinase receptor-3),
or NPM1 (nucleophosmin 1) [3,4]. Although novel high-
resolution genome-wide technologies have enabled the de-
tection of numerous gene mutations, the multistep process
of leukemogenesis is still poorly understood. In recent
years, many reports have proposed that additional patho-
genetic mechanisms, such as aberrant loss or gain of geneLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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relevance for AML pathogenesis [5-8].
Methylation of cytosines in the context of CpG dinucle-
otides is a stable and common epigenetic modification in
the mammalian genome. Most human gene promoters
overlap with CpG-rich regions, designated CpG islands
(CGIs), which are usually excluded from DNA methyla-
tion and, consequently, keep genes transcriptionally active.
Conversely, promoter methylation is commonly linked
with transcriptional silencing.
Hypermethylation and subsequent inactivation of genes
are hallmarks of AML pathogenesis [9,10]. Prominent ex-
amples include the epigenetically silenced tumor suppres-
sor genes CDH1 or p15/CDKN2B [11,12]. In addition,
gene hypomethylation is frequently found in myeloid
malignancies. The mechanistic link, however, between
promoter hypomethylation and tumorigenesis is incom-
pletely understood. Global hypomethylation is common
in many cancers, including AML, and is suspected to
destabilize genome integrity by re-activating retrotran-
sposons [6,13,14]. Alterations in DNA methylation con-
tribute to initiation, expansion, and evolution of the
leukemic clone and promoter hypermethylation is a fre-
quent observation in specimens of patients with MDS
and AML [15-17]. The mechanisms underlying the es-
tablishment of aberrant DNA methylation patterns are
still largely unknown. Aberrant DNA methylation might
be explained by the aberrant binding of transcription fac-
tors to their genomic target sequences. Transcription fac-
tor binding may prevent DNA methylation at these
sequences, while diminished binding may result in de novo
DNA methylation [18].
To gain a better insight into the molecular mecha-
nisms and pathways underlying AML onset and progres-
sion, different mouse models recapitulating human AML
have been generated, many based on the prevalent fu-
sion genes AML1/ETO, PML/RARA or MLL/ENL (for
review see [19]). These models mimic various human
leukemogenic processes in the context of distinct disease
genotypes and phenotypes associated with the different
forms of AML [20].
Targeted deletion of an upstream regulatory element of
the mouse gene Sfpi1 (common human name SPI1) en-
coding the transcription factor PU.1, a key hematopoietic
regulator for myeloid differentiation, results in homozy-
gous PU.1 hypomorphs that develop AML (or much less
frequently T-cell lymphomas) after a latency of 3 to
8 months [21,22]. As a consequence of reduced PU.1 ex-
pression in homozygous animals, epigenetic alterations of
tumor suppressor genes are suspected to be involved in
leukemogenesis. A previous screen of those animals devel-
oping a lymphoma but not an AML phenotype revealed
promoter hypermethylation of the tumor-suppressor gene
Id4 [21].Here, we provide a first comprehensive characterization
of the methylome at CGIs in bone marrow (BM) cells
from PU.1 hypomorphic animals during onset and pro-
gression of AML. Genome-wide DNA methylation screen-
ing during the process of leukemogenesis reveals the
extent as well as the spatial and temporal distribution of
altered DNA methylation. We aimed at identifying early
differentially methylated genes preceding the fully estab-
lished AML phenotype. Early differentially methylated
genes may contribute to onset and progression of the dis-
ease, while the far more abundant and diverse differen-
tially methylated genes at the late leukemic disease stage
may reflect clonal diversification of AML and bystander
events. We propose that hypomorphic PU.1 expression
contributes to the initiation of aberrant DNA methylation
of PU.1 target genes. Our study uncovers known and
novel targets of aberrant epigenetic regulation occur-
ring at onset and during progression of AML and,
hence, may help to develop novel therapeutic strategies
by revealing new pharmacologic targets at different
stages of the disease.
Methods
Animals, sample collection and histopathology
Transcription factor PU.1 hypomorphic Balb/c mice
with a homozygous deletion of an upstream regulatory
element of gene Sfpi1 encoding PU.1 were described
previously [21,22]. Whole BM of age- and gender-
matched homozygous wild-type (PU.1-wt) and PU.1
knockdown (PU.1-kd) mice were collected at three dif-
ferent disease stages. BM blast counts of PU.1-kd ani-
mals were used to define disease stages as preleukemic
stage (BM blasts <20%, age 4 to 18 weeks, n = 7), early
leukemic stage with residual non-malignant hematopoiesis
(BM blasts between 20% and 50%, 4 to 12 weeks, n = 5)
and late leukemic stage with full blown AML (>50%, 12 to
27 weeks, n = 7). From two of the seven animals of the late
leukemic stage, the blast count could not be determined
because the two mice died at the age of 22 to 24.5 weeks
shortly before sampling. Both mice were considered late
leukemic since they displayed phenotypic characteristics
of their stage, such as enlarged spleens. BM cells were
freshly collected from mouse femurs flushed with cold
phosphate-buffered saline. Bone sections from forelegs
were stained with hematoxylin and eosin and subjected to
histopathological inspection for assessment of the disease
stages.
Mouse BM cells were collected from the femorae, tib-
iae and iliae of PU.1-wt and preleukemic PU.1-kd mice
by gentle crushing in Iscove’s modified Dulbecco’s
medium. To confirm that the selected PU.1-kd animals
were preleukemic, a May-Grünwald/Giemsa staining
was performed on BM cytospins. The blast count was
below 20% in each animal. Five PU.1-wt animals were
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animals, two groups with four preleukemic animals per
group were collected. Murine lineage-depleted BM cells
were isolated essentially as described in [23]. Low dens-
ity mononuclear cells (LDMNCs) were purified by
density gradient centrifugation using Histopaque 1083
(Sigma-Aldrich, Taufkirchen, Germany). LDMNCs were
stained with the following rat anti-mouse biotin-
conjugated lineage markers (all from BD Biosciences,
Franklin Lake, NJ, USA): anti-CD5 (53-7.3), anti-CD8a
(53-6.7), anti-CD11b (M1/70), anti-CD45R/B220 (RA3-
6B2), anti-Ly-6G/Ly-6C (RB6-8C5) and anti-TER-119
(TER-119). The labeled LDMNCs were subsequently
incubated with Biotin Binder Dynabeads (Life Tech-
nologies, Darmstadt, Germany) and the lineage-positive
cells were depleted using a Dynamag-15 magnet, result-
ing in lineage-depleted cells. The lineage-depleted cells
were stained with the following panel of antibodies: FITC-
conjugated rat anti-mouse CD34 (RAM34; eBioscience,
Frankfurt, Germany); eFlour®450-conjugated rat anti-mouse
CD16/32 (93, eBioscience); APC-conjugated rat anti-
mouse CD127 (A7R34, eBioscience); PE-conjugated rat
anti-mouse CD117/c-Kit (2B8, eBioscience); APC-Cy7-
conjugated rat anti-mouse Ly-6A/E/Sca-1 (D7; BD Biosci-
ences, Heidelberg, Germany); and PE-Cy7-conjugated
Streptavidin (eBioscience). Lineage-negative, CD127-, c-
Kit+, Sca-1- cell fractions corresponding to granulocyte-
macrophage progenitor cells (GMPs; CD16/32+, CD34+),
common myeloid progenitor cells (CMPs; CD16/32-,
CD34+), and megakaryocyte-erythroid progenitor cells
(MEPs; CD16/32-, CD34-) as well as the lineage-negative,
CD127-, c-Kit+, Sca-1+ cell (LSK) fraction were then pro-
spectively isolated using a BD FACSAria I, II or III flow
cytometer (BD Biosciences). All animal experiments were
performed in accordance with the institutional guidelines
of the German Cancer Research Center and were ap-
proved by the Regierungspräsidium Karlsruhe, Germany.
MDS patient samples from whole BM (n = 149) and
from peripheral blood (n = 1) reflecting the entire disease
spectrum as displayed by the World Health Organization
(WHO) classification were obtained from the Department
of Hematology, Oncology and Clinical Immunology,
Heinrich-Heine University, Düsseldorf, Germany with
patient informed consent and the University Clinic
Düsseldorf review board approval in accordance with
the Declaration of Helsinki. The sample set contained
the following MDS subgroups: MDS with del(5q) (5q-,
n = 5), refractory anemia (RA, n = 6), refractory anemia
with ringed sideroblasts (RARS, n = 8), refractory cyto-
penia with multilineage dysplasia (RCMD, n = 43), refrac-
tory cytopenia with multilineage dysplasia and ringed
sideroblasts (RCMD-RS, n = 30), refractory anemia with ex-
cess of blasts type I and II (RAEBI, n = 18; RAEBII, n = 28),
chronic myelo-monocytic leukemia type I and II (CMMLI,n = 10; CMMLII, n = 2). Normal karyotype AML patient
samples from whole BM (n = 46) and from peripheral blood
(n = 5) were obtained from the Department of Hematology/
Oncology, University Medical Center, Freiburg, Germany
with patient informed consent and the University Clinic
Freiburg review board approval in accordance with the
Declaration of Helsinki. Healthy granulocytes were isolated
from blood of 14 healthy donors using Leukosep (Greiner
bio-one, Frickenhausen, Germany) according to the manu-
facturer's instructions. CD34+ cells were from two healthy
female and one healthy male donor (median age 36 years)
and purchased from Lonza (Verviers, Belgium).
DNA and RNA extraction
DNA and RNA were extracted from mouse BM using
the Allprep Mini Kit (QIAGEN, Hilden, Germany) ac-
cording to the manufacturer’s protocol and stored at 4°C
(DNA) or -80°C (RNA).
DNA of human MDS and AML samples was isolated
with the QIAmp DNA Mini Kit (QIAGEN) according to
the manufacturer’s instructions.
Methyl-CpG immunoprecipitation
Methyl-CpG immunoprecipitation (MCIp) was performed
as described previously [24]. In brief, a total of 2.5 μg DNA
was sonicated with the Bioruptor NextGen (Diagenode,
Liege, Belgium) to fragments of 100 to 600 bp as monitored
on a 1.5% agarose gel. MCIp enrichment of highly
methylated DNA was performed, as described, with
minor modifications using SX-8G IP-Star robot (Diage-
node). Sonicated DNA was enriched with 90 μg puri-
fied methyl-CpG-binding domain-Fc protein coupled
to 60 μl protein A-coated magnetic beads (Diagenode).
DNA was eluted by incubation with increasing NaCl
concentrations (fraction A, 300 mM; B, 400 mM; C,
500 mM; D, 550 mM; E, 1,000 mM). Desalted eluates
were controlled for enrichment of methylated DNA by
real-time PCR analyzing the imprinted gene Mest. The
non-methylated allele elutes at low-salt while the methyl-
ated allele elutes at high-salt concentration.
Methylome profiling by microarray analysis
Highly methylated DNA, corresponding to fraction E of
the enrichment procedure, from age- and gender-matched
PU.1-kd and PU.1-wt animals was labeled with Alexa 3
(PU.1-wt) or Alexa 5 (PU.1-kd) and co-hybridized to a
mouse CGI array (Agilent, Böblingen, Germany) covering
the about 16,000 CGIs, represented by 88,358 probe se-
quences with a length of 45 to 60 bp per probe se-
quence, of the mouse genome (approximately 0.4%;
NCBI36/mm8). Henceforth, probe sequences are desig-
nated 'probes' throughout this study and 'differentially
methylated probes' (DMPs), if they were differentially
methylated between PU.1-kd and PU.1-wt animals.
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the probes to 5,285 gene promoters, 7,872 gene bodies,
480 locations downstream of genes and 1,869 locations
with unknown genomic feature. Here, promoter probes
were defined as those being located 2,000 bp upstream to
500 bp downstream of a gene's transcription start site. In
all other cases, we followed the annotation of Agilent.
Microarrays were analyzed using a DNA microarray
scanner (Agilent) and Feature Extraction Software 10.5
(Agilent) with the ChIP protocol setting. Data process-
ing and statistical analyses were done within the R statis-
tical environment, v. 2.13.1 [25]. Background correction
and log 2-ratio transformation were performed according
to the NormExp method with offset = 50; any intensity that
is less than 0.5 after background subtraction is reset to be
equal to 0.5 [26]. Variation between co-hybridized samples
was reduced by intensity-based LOESS normalization on
rank-invariant probes and negative controls [27].
The CGI array data of this study has been deposited at
the NCBI Gene Expression Omnibus [28] under acces-
sion number GSE37315.
Quantitative DNA methylation analysis
The degree of DNA methylation was determined by
MALDI-TOF mass spectrometry (MassARRAY, Seque-
nom, San Diego, USA) as previously described [29].
Amplicon primers (Additional file 1) flanked genomic
stretches that covered at least one of the hypermethy-
lated probes represented on the CGI array. In vitro
methylated standard DNA served as control. Unmethy-
lated DNA was produced using the REPLI-g Mini Kit
(QIAGEN) and purified with the QIAmp DNA Mini Kit
(QIAGEN). Half of the unmethylated DNA was methyl-
ated using M.SSSI enzyme and purified with the QIA-
quick gel extraction kit (QIAGEN). Unmethylated and
methylated DNA was mixed to obtain different ratios for
the standard DNA (0%, 20%, 40%, 60%, 80% and 100%
DNA methylation).
Overlap of publicly available chromatin immunoprecipitation
sequencing data with methylome data
Genomic coordinates from publicly available chromatin
immunoprecipitation sequencing (ChIP-Seq) data of tran-
scription factor PU.1 (NCBI37/mm9) [30] were converted
to the NCBI36/mm8 (2006) genome by using the lift over
tool of the UCSC Genome Browser [31]. In total, 22,625
out of 22,720 peak regions could be successfully con-
verted. The PU.1 ChIP coordinates were overlapped with
genomic coordinates of the preleukemic hypermethylated
genes, and Fisher's exact test was used to test for signifi-
cant enrichment of the PU.1 ChIP peaks. We randomly
permutated the PU.1 ChIP-Seq peaks 1,000 times over the
genomic coordinates of the preleukemic hypermethylated
CGIs and compared the randomly permutated numberswith the actual numbers of PU.1 ChIP-Seq peak/preleuke-
mic hypermethylated CGI overlap.
Statistical analysis
Following CGI array normalization, one class signifi-
cance analysis of microarrays (SAM; package samr, ver-
sion 2.0 [32]), was performed for each disease stage
separately to find significantly hyper- and hypomethy-
lated probes between PU.1-kd and PU.1-wt mice with a
false discovery rate of 5%. Principal component analysis
(PCA; package pcaMethods, version 1.36.0) was per-
formed using the array methylation patterns to analyze
homogeneity between individual animals at the molecu-
lar level in the course of the disease.
Unsupervised clustering with Euclidian distance and the
average agglomeration method was used for clustering
MassARRAY data. Unsupervised clustering was per-
formed by multiscale bootstrap resampling [33] (package
pvclust, version 1.2.2) to calculate approximately unbiased
(AU) P-values for each cluster in the result of hierarchical
clustering. The number of permutations was set to 1,000.
Mann-Whitney U test was performed to test for methy-
lation differences derived from MassARRAY data between
PU.1-kd and PU.1-wt animals and between AML/MDS
samples and healthy granulocytes/CD34+ cells.
The computational analysis was performed by custom
Perl scripts and the motif discovery was conducted with
the software suite HOMER (Hypergeometric Optimization
of Motif EnRichment) [34].
Pathway analysis
Pathway analysis was performed using genes that were
represented by at least two DMPs of the preleukemic
stage through the use of Qiagen’s Ingenuity® Pathway
Analysis [35].
Results
Disease progression is associated with alterations in
global DNA methylation
In order to determine DNA methylation changes in the
progression of leukemic cells, we used the murine
AML model driven by hypomorphic expression of the
hematopoietic transcription factor PU.1 and MCIp as a
screening tool. MCIp allows the enrichment of methyl-
ated DNA from cell populations and, in this way, is
conceptually different to whole genome bisulfite se-
quencing. We monitored the proportion of BM blasts
in PU.1 hypomorphic mice (PU.1-kd) that develop an
AML-like malignancy. According to blast counts, we
defined the three disease stages as preleukemic (BM
blasts <20%, n = 7, median age 4 to 18 weeks), early
leukemic (BM blasts 20 to 50%, n = 5, 4 to 12 weeks)
and late leukemic stage (BM blasts >50%, n = 7, 12 to
















































Figure 1 (See legend on next page.)
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Figure 1 Disease progression and accompanying global DNA methylation in the PU.1 mouse model. (A) Representative histological
sections of mouse forelegs showing BM of PU.1-wt and PU.1-kd animals of different disease stages (preleukemic stage, BM blasts <20%; early leukemic
stage with residual non-malignant hematopoiesis, BM blasts between 20% and 50%; late leukemic stage with full blown AML, BM blasts >50%). Sections
were stained with hematoxylin and eosin; 400× original magnification. (B) PCA based on normalized relative probe intensities between PU.1-kd versus
PU.1-wt animals. In total, 88,358 array probes per sample were analyzed. Principal component (PC)1 explains the largest variances of the entire data set
and implicates diversification of the DNA methylation patterns in late leukemic stage animals. (C) Circos plot showing the hypermethylated
probes of the three disease stages (preleukemic, early leukemic, late leukemic). The outer circle indicates the G-banded mouse chromosomes,
the differently colored lines in the inner circles represent hypermethylated probes of the three stages. (D) Percentage of hyper- and hypomethylated
probes (DMPs) in the different disease stages (preleukemic, early leukemic, late leukemic). SAM was performed to identify the DMPs. Out of 88,358
probes, 20,787 were aberrantly methylated in at least one disease stage. (E) Venn diagrams showing unique and common hyper- and hypomethylated
probes in different disease stages.
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ous, late leukemic stage animals displayed pronounced
morbidity and suffered from eye and ear infections and
from massive spleno- and hepatomegaly as previously
described [22]. Using CGI tiling microarrays, we cohy-
bridized MCIp-enriched, highly methylated DNA of the
PU.1-kd animals with that of age- and gender-matched
PU.1-wt. Similarity between the PU.1-kd animals with
respect to the DNA methylation patterns was tested by
PCA using the signal intensity ratio (M-value) of the
array probes as a measure for enrichment (Figure 1B).
The largest variance as explained by principal component
1 (PC1) was observed for individuals of the late leukemic
disease stage that clearly separated them from preleukemic
and early leukemic stage animals. In addition, late leukemic
stage animals showed a more diverse distribution, suggest-
ing a larger inter-individual heterogeneity of DNA methy-
lation patterns; preleukemic and early leukemic stage
animals grouped together.
Early aberrant DNA methylation is followed by the
diversification of hypermethylation in the late leukemic
disease stage
We used the array-derived M-values to characterize the
three disease stages by SAM. Of the 88,358 probes,
20,787 (23.5%) were aberrantly methylated in at least
one stage of the disease. Aberrant DNA methylation was
equally distributed across the genome, and no chromo-
some was preferentially hypermethylated (Figure 1C) or
hypomethylated (Additional file 2). In the preleukemic
stage, 1,184 (1.34%) hyper- and 802 (0.91%) hypomethy-
lated probes were found, covering 762 and 504 genes or
other genomic locations, respectively (Additional file 3).
Both numbers slightly decreased in the early leukemic
stage, suggesting either partial reversion of initial methy-
lation changes or concomitant molecular processes other
than aberrant DNA methylation (for example, genetic al-
terations) driving malignant clone selection (Figure 1D).
The number of hypermethylated, but not that of hypo-
methylated probes abruptly increased in the late leukemic
stage to 19,316 (21.9%), covering 5,465 genes or other gen-
omic locations (Figure 1D). Within the respective stages,several unique hyper- and hypomethylated probes were
observed. For example, 162 probes were uniquely
hypermethylated in the preleukemic stage, but were
unchanged or even hypomethylated in the other stages.
Throughout all stages, 297 (0.3%) probes were com-
monly hypermethylated and 47 probes were commonly
hypomethylated (Figure 1E).
We randomly selected 40 hypermethylated genes of
the preleukemic stage for technical validation by quanti-
tative high-resolution methylation analysis using Mas-
sARRAY. For 34 genes (85%), hypermethylation in
preleukemic versus matched PU.1-wt animals was con-
firmed (P < 0.05; Figure 2A; Additional file 4) and, hence,
indicated high reliability of our CGI array data. Hyper-
methylation was also confirmed for 36 (90%) in the early
leukemic and for 37 (92.5%) in the late leukemic stage.
Moreover, unsupervised clustering using the quantitative
methylation data recapitulated the results of the global
PCA-based analysis and discriminated the PU.1-kd from
the PU.1-wt animals (Figure 2A).
We observed a significant gradual increase of methyla-
tion levels with disease progression in the majority of ana-
lyzed genes as exemplified by Fzd5 and Fzd8 (Figure 2B,C).
Fzd5 methylation was 12.1% (range 6.8 to 21.3%) in
PU.1-wt animals and 33.4% (range 18.2 to 44.9%),
40.9% (range 34 to 47.8%) and 50.4% (range 39.8 to
92.8%) in preleukemic, early leukemic and late leukemic
stage animals, respectively. The stage-dependent in-
crease of Fzd8 methylation was similar to that of Fzd5,
starting with 22.8% (range 15.9 to 37.3%) in PU.1-wt
animals and increasing to 30.6% (range 24.3 to 44.7%),
35.4% (range 28.1 to 41.9%) and 44.8% (range 36.1 to
67.2%) in the preleukemic, early leukemic and late
leukemic stage animals, respectively.
Acute myeloid leukemia-specific methylation changes
To ensure that the observed changes in DNA methylation
are not the result of tissue-specific methylation patterns
and, thus, reflect differences in cell type composition, we
analyzed Fzd5, Fzd8 and eight additional differentially
methylated regions in four hematopoietic cell types, LSK






































































































































































































































































Figure 2 Validation of screening results by quantitative DNA methylation analysis (MassARRAY). (A) Heatmap showing the average
methylation levels in 40 gene-specific amplicons (columns) and individual PU.1-kd and PU.1-wt animals (rows). Methylation levels range from 0%
(light green) to 100% (dark blue). Grey boxes represent missing values. The bar to the left of the heatmap indicates different disease stages (black,
preleukemic; blue, early leukemic; red, late leukemic; green, PU.1-wt). Unsupervised clustering discriminates PU.1-kd and PU.1-wt animals. (B,C)
DNA methylation levels of Fzd5 (B) and Fzd8 (C). Average amplicon methylation is shown for different animals of the different stages. The black
bar represents the median methylation within one stage. Mann-Whitney U test was used to test for differences between the different disease
stages (*P < 0.05, **P < 0.01, ***P < 0.001). (D,E) Methylation levels (heatmaps on top, bar graphs below) of Fzd5 (D) and Fzd8 (E) amplicons in sorted
cells of PU.1-wt animals and two groups of preleukemic PU.1-kd animals, KD1 and KD2. The sorted cells comprise LSKs (lineage-negative, Ska1-positive,
c-kit-negative cells), CMPs (common myeloid progenitor cells), GMPs (granulocyte-macrophage progenitor cells) and MEPs (megakaryocyte-erythroid
progenitor cells). The heatmaps display single CpG units (columns) of PU.1-kd or PU.1-wt animals (rows). Methylation values range from 0% (light
green) to 100% (dark blue). The bar graphs show average methylation (y-axis) of the different amplicons. In (D), analysis of KD2-GMP failed, indicated
by grey CpG units in the heatmap and missing value in the bar graph.
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kd BM, respectively, and which represent different stages
of hematopoietic commitment. We found both genes to
be similarly hypermethylated in all four cell types in PU.1-
kd BM (Figure 2D,E; Additional file 5). This indicates that
hypermethylation at these loci is an early event that is spe-
cific for PU.1-kd and does not just reflect the expansion of
specific hematopoietic compartments. In summary, our
quantitative methylation data indicate dynamic changes
from onset to the late leukemic stage of the disease. The
correlation between DNA methylation level and myelo-
blast infiltration suggests that aberrant DNA methylationis a feature of the malignant clone. Early aberrant DNA
methylation at specific loci, in turn, can ubiquitously be
found in the myeloid compartment and may characterize
the (pre)-malignant clone in its early stage.
Early targets of aberrant DNA methylation in the PU.1
mouse model are relevant for the pathogenesis of human
myeloid malignancies
To identify genes potentially involved in the onset of
AML, we looked for overlaps between the list of 1,229
genes or other genomic locations indicated by aberrantly
methylated probes in the preleukemic stage (Additional
Sonnet et al. Genome Medicine 2014, 6:34 Page 8 of 16
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wide DNA methylation data derived from the HELP
(HpaII tiny fragment enrichment by ligation-mediated
PCR) assay in human MDS and AML [17]. We detected
291 common genes with MDS-associated DNA methyla-
tion targets (5,390 in total) and 30 common genes with
the AML gene list (475 de novo targets in total) (Additional
file 6). These overlaps corroborate the relevance of the
animal model for acute human myeloid malignancies.
Well-known examples of human leukemogenesis, such
as RUNX1, CEBPA, and ABL1, were aberrantly methyl-
ated in both the murine preleukemic stage and in hu-
man MDS. Remarkably, the ratios between overlapping
genes and the aberrantly methylated human disease
genes (291/5,390 ~ 0.05 for MDS and 30/475 ~ 0.06 for
AML) were rather similar, suggesting that the mouse
model was not confined to only a distinct disease type
of either MDS or AML.
We tested by gene ontology analysis (Ingenuity Path-
ways Analysis) whether the set of aberrantly methylated,
preleukemic genes represented functional groups of
genes or pathways relevant for AML pathogenesis.
Among several partially overlapping signaling pathways,
Wnt/β-catenin and embryonic stem cell signaling were
prominently overrepresented (Additional file 7). These
pathways are known to be involved in onset and pro-
gression of human malignancies, including AML [36,37].
Moreover, Wnt signaling has already been linked to the
inappropriate regulation of the PU.1 transcription factor
associated with T-cell lymphoma in mice [21].
Since the Wnt signaling genes Fzd5 and Fzd8 showed
enhanced CGI hypermethylation with increasing disease
stage (Figure 2B, C), we examined the methylation state of
the homologous human CGI sequences in sets of MDS
(15.7% and 8.8% median DNA methylation for FZD5 and
FZD8, respectively) and normal karyotype AML (42.5%
and 15.5%) patient samples. Despite large methylation
ranges in the patient samples, both genes proved signifi-
cantly hypermethylated in both MDS and AML compared
to granulocytes (6.3% and 6.7%) and CD34+ cells (25.6%
and 7.7%) from healthy donors; hypermethylation was
more pronounced in the latter (Figure 3). No significant
difference could be detected between different risk groups
in the MDS patients according to IPSS (International
Prognostic Scoring System, consisting of the fraction of
BM blasts, number of cytopenias and the cytogenetic risk
group) or to WHO classification subgroups combined by
blast count range (Additional file 8).
We selected three additional genes, PRDM16, ROBO3,
and CXCL14, that displayed promoter hypermethylation
already in the preleukemic or early leukemic stage
(Additional file 4) for validation in human AML sam-
ples. Thus far, these genes have not been shown to be ab-
errantly methylated in human AML; however, PRDM16and ROBO3 are differentially methylated in MDS [17].
PRDM16 is a fusion partner of RPN1, RUNX1, and other
genes in hematopoietic malignancies [38,39], and re-
arrangement of PRDM16 was associated with poor prog-
nosis [38]. ROBO3 is hypermethylated in cervical cancer
[40]. CXCL14 is important in the progression of many ma-
lignancies, including colorectal cancer [41], and is epige-
netically silenced in lung and prostate cancer [42,43]. All
three genes showed promoter hypermethylation in the
AML samples, and that of ROBO3 and CXCL14 reached
statistical significance (P < 0.05; Additional file 9).
Loss of PU.1 binding contributes to aberrant DNA
methylation
Transcription factors bound to their genomic target se-
quences may prevent DNA methylation at these se-
quences, whereas reduction or loss of transcription
factor binding may result in de novo DNA methylation
[18]. We hypothesized that hypomorphic expression of
the PU.1 transcription factor entails reduced DNA bind-
ing of PU.1; this reduction, in turn, may contribute to
aberrant DNA methylation patterns of PU.1 target genes.
Therefore, we searched for overrepresented sequence mo-
tifs within all preleukemic hypermethylated CGIs (787)
and found a significant overrepresentation of a PU.1 bind-
ing motif among these CGIs (P = 1e-11; Figure 4A). Fur-
thermore, the search for known binding factors revealed a
significant overrepresentation of binding sites for the E2f
family and for FoxA1 (P = 0.01; Additional file 10), the
former known to contribute to hematopoiesis [44], the lat-
ter known to be involved in normal and cancer develop-
ment [45]. An additional search for the consensus PU.1
binding motif GAGGAA in the complete mouse genome
(mm8, 2006) revealed 704,291 sites of which 99 over-
lapped with the preleukemic hypermethylated CGIs. Ran-
dom permutation of the PU.1 motif resulted in an
average of only 57 matches, indicating that the PU.1
motif is enriched in the preleukemic hypermethylated
CGIs (Fisher's exact test, P < 0.001). Taken together, our
motif search revealed a variety of binding sites for
known transcription factors relevant in hematopoiesis,
but also novel motifs of yet unknown function.
To identify PU.1 target genes associated with the pre-
leukemic hypermethylated CGIs, we searched for over-
laps between the genomic coordinates of PU.1 binding
sites obtained from publicly available PU.1 ChIP-Seq
data [30] and the coordinates of the preleukemic hyper-
methylated CGIs. We found an overlap of 109 genes or
other genomic locations (Figure 4B). In a more stringent
search, we selected only the preleukemic CGIs that were
covered by at least two hypermethylated probes. Here,
17 from 214 preleukemic hypermethylated CGIs over-
lapped with a PU.1 ChIP peak (Figure 4B; Additional file
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Figure 3 Hypermethylation of FZD5 and FZD8 in MDS and AML patients. (A-D) Heatmaps and dotplots of amplicons from FZD5 (A,C) and
FZD8 (B,D) in MDS (top) and AML (bottom) patients compared to healthy granulocytes/CD34+ cells. The heatmaps display methylation levels of
single CpG units (columns). Methylation values range from 0% (light green) to 100% (dark blue). Differently colored bars to the left of the heatmaps
indicate MDS (M), AML (A), healthy granulocytes (G) and CD34+ cells (C). Schemes above the heatmaps display the gene (black bar), transcription start
(arrow), the relative location of the CpG island (CGI) and the amplicon analyzed (MA). The dotplots show average amplicon methylation levels of
individual MDS/AML patients, healthy granulocytes (HG) and CD34+ cells (CD34). The median methylation in a group is depicted by a black bar
(median methylation of FZD5 was 15.7% in MDS samples and 42.5% in AML samples; median methylation of FZD8 was 8.8% in MDS samples
and 15.5% in AML samples). Mann-Whitney U test was used to test for differences between MDS/AML samples, healthy granulocytes and
CD34+ cells (*P < 0.05, **P <0.01).
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http://genomemedicine.com/content/6/4/34hypermethylated genes was significant for both search
stringencies (P < -2.2e-16 for 109/787 genes and P =
0.002049 for 17/214 genes). From the 17 genes identified
under higher stringency, we selected three gene pro-
moters, Bcor, Itpka, and Hes6, for validation by quantita-
tive methylation analysis in PU.1-kd and -wt animals.
Bcor mutations have been found in AML [46], Itpka
contributes to differentiation of human embryonic stem
cells [47] and is downregulated in oral squamous cellcarcinoma [48], and Hes6 is overexpressed in glioma
and breast cancer [49,50]. From those overlapped re-
gions only covered by a single hypermethylated probe
(109; Figure 4B), we selected a fourth gene, Tal1, a
known PU.1 target, because of its function in normal
hematopoiesis and leukemogenesis [51,52]. Hypermethy-
lation of all four PU.1 target genes was confirmed by Mas-
sARRAY in the PU.1-kd samples (Figure 4C; Additional





































































Figure 4 PU.1 motifs and binding peaks are enriched among the preleukemic hypermethylated genes. (A) Enriched sequence motifs
within the preleukemic hypermethylated genes. (B) Venn diagram showing the number of overlapping and non-overlapping genomic coordinates of
preleukemic hypermethylated CGIs (green) and publicly available ChIP-Seq data (red). Numbers in brackets represent a more stringent analysis, namely
preleukemic hypermethylated genes represented by at least two hypermethylated probes. (C) Validation of PU.1 target gene Bcor by MassARRAY.
Heatmaps display methylation levels of single CpG units (columns) in different disease stages (rows). Differently colored bars to the left of
the heatmaps display preleukemic (P, black), early leukemic (EL, blue), late leukemic (LL, red), wild type (W, green) and standard (S, grey).
Methylation values range from 0% (light green) to 100% (dark blue). The scheme above the heatmaps displays the gene (black bar), transcription
start (arrow), the PU.1 ChIP peak (PU1), the relative location of the CpG island (CGI) and the two MassARRAY amplicons (MA). The dotplots below the
heatmaps show the average amplicon methylation levels of wild-type animals and different disease stages. The median methylation in a sample
group is indicated by a black bar. Mann-Whitney U test was used to test for differences between wild type and stages and between stages (*P < 0.05,
**P <0.01, ***P < 0.001).
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http://genomemedicine.com/content/6/4/34cell types, LSK, CMP, GMP and MEP. We found all genes
similarly methylated in all cell types (Additional file 5).
Of the four PU.1 target genes, BCOR, ITPKA and TAL1
were also found aberrantly methylated in a recent genome-
wide screen of MDS patients [17]. We examined the
methylation levels of the four genes in human AML sam-
ples and observed significant hypermethylation compared

























Figure 5 Hypermethylation of PU.1 target genes in AML samples. (A-
and ITPKA (D), by MassARRAY in human AML samples compared to healthy
Figure 3. Median methylation values in AML samples are as followed: BCOR
1, 4.2%; TAL1 amplicon 2, 4.6%; ITPKA, 5.9% (*P < 0.05, ***P <0.001).and TAL1, while BCOR showed a trend towards hyperme-
thylation in a subgroup of AML patients (Figure 5). Add-
itionally, we could relate PU.1 mRNA expression with
target gene methylation in a set of 26 AML patients, where
the expression differed by a factor of up to six-fold. How-
ever, no correlation between PU.1 mRNA expression and
methylation at presumed PU.1 binding sites in the pro-


















D) Validation of four PU.1 target genes, BCOR (A), HES6 (B), TAL1 (C)
granulocytes (HG) and CD34+ cells. For details, refer to the legend of
, 4.6%; HES6 amplicon 1, 5.6%; HES6 amplicon 2, 49.7%; TAL1 amplicon
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binding contributes to the establishment of aberrant
DNA methylation patterns. Similarities between DNA
methylation patterns of the PU.1-kd mice and human
MDS and AML patients underscore the benefit of study-
ing early epigenetic changes in the mouse model for the
identification of genes potentially involved in onset and
progression of the disease. We present various novel
genes associated with AML as potential early targets for
aberrant DNA methylation during leukemogenesis.
Discussion
AML pathogenesis is a complex multistep process that
involves an interplay of genetic and epigenetic aberra-
tions. The time from disease onset to its full-blown clin-
ical picture requires detailed knowledge about the
timing of disease-driving molecular mechanisms to suc-
cessfully interfere with these processes by targeted ther-
apy. Here, we addressed the question whether epigenetic
aberrations already contribute to the early events and
processes in AML pathogenesis by utilizing a murine
AML progression model with a stable down-regulation
of the hematopoietic transcription factor PU.1 [22]. We
characterized DNA methylation dynamics over three
stages of disease development and demonstrated that
distinct DNA methylation changes occur early and subse-
quently expand during leukemogenesis. The reliability and
relevance of methylation assessment by our genome-wide,
array-based approach was corroborated by independently
confirming 34 of 40 selected genes/chromosomal locations
using quantitative, high-resolution mass spectrometry.
PCA with the DNA methylation values of all CGI
array probes distinguished late leukemic stage from pre-
leukemic and early leukemic stage animals. Preleukemic
animals with low or absent myeloblasts already exhibited
a high number of hypermethylated sequences, indicating
extensive involvement of epigenetic mechanisms at this
stage. These sequences represented 762 genes or other
genomic locations. Approximately one-fourth of the pre-
leukemic hypermethylated sequences were consistently
hypermethylated throughout all leukemogenic stages,
underscoring the pathogenic relevance of the affected
genes for disease initiation and progression. Compared
to hypermethylation, hypomethylation was considerably
less abundant, probably due to its preferential occur-
rence outside of CGIs. Thus, our findings highlight that
CGI hypermethylation accompanies AML onset and,
therefore, may contribute to AML development.
From the preleukemic to the early leukemic stage, the
number of hypermethylated probes appeared largely
stable. At the late leukemic stage, however, the number
of hypermethylated probes strikingly increased approxi-
mately 20-fold, accompanied by genomic diversification
of DNA methylation. Cluster analysis of quantitativemethylation values clearly discriminated between PU.1-
wt and PU.1-kd animals.
The increase of aberrant DNA methylation abundance
in the late leukemic stage cannot simply be explained by
the mere increase in blast counts, but might rather be
the consequence of a vigorous 'epigenetic' clonal evolu-
tion or of severe disturbance of the epigenetic machin-
ery. When we examined the methylation levels in
diverse hematopoietic progenitors at the preleukemic
stage, all cell types displayed hypermethylation, similar
to that of the bulk of myelogenic cells at this stage. Ac-
cordingly, we could so far neither dissect the AML cell
of origin nor attribute leukemic expansion to the expan-
sion of a distinct hematopoietic lineage.
Our study supports a model of an epigenetic outburst
targeting distinct regions early in disease progression.
This could be a consequence of genetic alterations in en-
zymes regulating epigenetic patterns, such as gene muta-
tions found in human myeloid malignancies, including
DNMT3a, TET2, IDH1, IDH2, EZH2, or ASXL1 [53].
With respect to the dramatic outburst of aberrant DNA
methylation in the late stage, our AML-like mouse model
differs from a recently reported chronic lymphocytic
leukemia-like mouse model, where early DNA methyla-
tion events are followed by a gradual increase of aber-
rantly hypermethylated genomic regions over time [54].
We identified a wealth of known and novel AML-
associated genes, epigenetically altered already at the
preleukemic disease stage, and provide a repository of
762 early hypermethylated and 504 hypomethylated
genes, together constituting a valuable resource for in-
vestigating potential key pathogenic factors in AML.
Since methylation of cytosine is a reversible epigenetic
modification, and demethylating drugs are already used
in the clinical setting for treatment of both MDS and
AML patients [55,56], the novel early candidates identi-
fied in this study may point towards druggable mecha-
nisms and pathways for targeted therapy. In line with
observations by others [36,37], a prominent role at dis-
ease onset can be ascribed to the Wnt signaling pathway,
since members of this pathway, Fzd5, Fzd8, Fzd10, and
Wnt3 (Additional file 7), were overrepresented among
the early aberrantly methylated targets. The link between
Wnt signaling and the PU.1-kd-driven AML mouse
model is corroborated by earlier observations that PU.1
is targeted by Wnt pathway members [21].
We detected a considerable overlap between early ab-
errantly methylated genes and genes involved in human
myeloid malignancies (MDS and AML) [17], indicating
the relevance of the observed epigenetic changes in the
mouse model for human disease. Hypermethylated genes
in the preleukemic stage such as Cebpa and Hic1 have
already been described as being hypermethylated as well
in AML [57,58]. Moreover, normal karyotype AML and
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hypermethylation of the Wnt pathway members FZD5
and FZD8, as observed in the mouse model. We con-
firmed three additional candidates, PRDM16, ROBO3
and CXCL14, to be hypermethylated in the AML patient
cohort. So far, none of these five genes has been validated
as being aberrantly methylated in AML by a quantitative
high resolution method, albeit FZD5, FZD8, ROBO3 and
PRDM16 have been found in other genome-wide methyla-
tion screens of MDS samples [17]. The concordant pres-
ence of aberrant methylation in these candidate genes
already in early stages of our mouse model as well as in
both MDS and AML suggests a disease driving potential
of these aberrations.
It has been shown previously that binding of transcrip-
tion factors to target DNA sequences may prevent their
methylation [18]. In line with this, knockdown of tran-
scription factor PU.1 was associated with preleukemic
hypermethylation at a considerable number of PU.1 tar-
get sequences derived from publicly available ChIP-Seq
data [30]. Looking closer at four selected PU.1 target
genes by quantitative methylation analysis, we confirmed
hypermethylation in both PU.1-kd animals and human
AML samples. However, a correlation between PU.1 mRNA
expression and methylation levels of the selected target
genes BCOR, HES6, ITPKA and TAL1 could not be demon-
strated in AML patients, suggesting other mechanisms than
mere PU.1 down-regulation to be required for hypermethy-
lation of these genes in human AML.
Taken together, our results suggest that the PU.1-kd
mouse is a valuable model to study epigenetic changes dur-
ing AML progression. The newly identified early hyper-
methylated genes are potential determinants for aberrant
DNA methylation patterns in the disease course and,
consequently, may contribute to disease development in
humans. Early epigenetic changes are suspected drivers of
malignancies and, hence, may offer the chance to identify
suitable drug targets for early therapeutic intervention. As
shown here, epigenetic profiling of tumor progression
models is a promising strategy to highlight the role of epi-
genetics in disease initiation and progression.
Conclusions
In the present study, we utilized a mouse model of
leukemogenesis to identify epigenetically altered gen-
omic loci on a global scale and to determine the timing
of altered epigenetic reprogramming. DNA methylation
profiling of the PU.1 mouse model of leukemogenesis
enabled detailed insight into the extent and dynamics of
aberrant epigenetic mechanisms and created a valuable
resource of early aberrantly methylated genes. We dem-
onstrate that DNA methylation changes occur along
AML pathogenesis in mice, and that these specific alter-
ations recapitulate the alterations seen in human myeloidmalignancies. Thus, this mouse model represents a suit-
able tool to investigate the molecular mechanisms leading
to epigenetic reprogramming. We found high numbers of
genes affected by epigenetic changes. The wealth of early
affected loci strongly argues for a prominent role of epi-
genetic mechanisms in the pathogenesis and progression
of MDS and AML.
Additional files
Additional file 1: A table listing the primers used for MassARRAY
analysis.
Additional file 2: A circos plot displaying the hypomethylated
probes in PU.1-kd animals. The outer circle represents the different
G-banded mouse chromosomes, lines in the inner circles depict significantly
hypomethylated probes of the different disease stages (preleukemic, early
leukemic and late leukemic from inner to outer).
Additional file 3: A table listing the aberrantly methylated probes
of the preleukemic stage. The table shows probe ID (column A),
chromosome (B), start (C), end (D), the genomic location (E), the
corresponding gene name (F), the location of the respective probe
(G to J), the methylation status in the preleukemic stage (K) and the
methylation status in the three disease stages (L,M).
Additional file 4: A figure displaying the validation of array-based
screening results by quantitative DNA methylation analysis
(MassARRAY). Forty preleukemic hypermethylated genes were randomly
selected for MassARRAY analysis (see also Figure 2 for Fzd5 and Fzd8).
Dotplots depict average methylation per amplicon and sample; the
median of a sample group is represented by a black bar. Mann-Whitney
U test was used to test for differences between wild type and the
different disease stages and also between the disease stages (*P < 0.05,
**P < 0.01, ***P ≤ 0.001).
Additional file 5: (A-H) The MassARRAY results for Prdm16 (A),
Robo3 (B), Bcor (C,D), Hes6 (E), Tal1 (F) and Itpka (G,H) in sorted cells
from preleukemic PU.1-kd mice and PU.1-wt animals. The sorted cells
include LSKs (lineage-negative, Ska1-positive, c-kit negative cells), CMPs,
GMPs and MEPs.
Additional file 6: A table showing the comparison between
aberrantly methylated genes of the preleukemic stage and
previously published genome-wide DNA methylation data. The two
tables show the overlap of genes of the preleukemic stage with publicly
available genome-wide methylation data in AML (left table) and MDS
(right table). Columns B and I indicate if the gene was hypermethylated
in the promoter region of the preleukemic hypermethylated genes.
Additional file 7: A table listing pathways that are enriched in the
aberrantly methylated genes of the preleukemic stage. Column A,
respective pathway; column B, log P-value; column C, enrichment score;
column D, gene names.
Additional file 8: A figure showing the DNA methylation of FZD5
and FZD8 in different risk groups of MDS patients. DNA methylation
in WHO groups (5q-, deletion of chromosome 5q; RA, refractory anemia;
RARS, refractory anemia with ringed sideroblasts; RCMD, refractory
cytopenia with multilineage dysplasia; RCMD-RS, refractory cytopenia with
multilineade dysplasia and ringed sideroblasts; RAEB, refractory anemia
with excess of blasts; CMML, chronic myelo-monocytic leukemia) or IPSS
(International Prognostic Scoring System) classification risk groups (low, Int1,
Int2, high) compared to healthy granulocytes are shown. Mann-Whitney U
test was used to test for differences between the risk groups/WHO
classification groups and healthy granulocytes (*P < 0.05, **P < 0.01,
***P ≤ 0.001).
Additional file 9: A figure depicting the quantitative determination
of DNA methylation in human AML samples. (A-C) Heatmaps (left)
and dotplots (right) of amplicons from PRDM16 (A), ROBO3 (B) and
CXCL14 (C) in AML patients, healthy granulocytes, and in CD34+ cells are
shown. Heatmaps display single CpG units (columns) of AML patients,
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http://genomemedicine.com/content/6/4/34healthy granulocytes and CD34+ cells. Differently colored bars to the left
of the heatmaps indicate AML (A, red), healthy granulocytes (G, green)
and CD34+ cells (C, grey). Methylation values range from 0% (light green)
to 100% (dark blue). Schemes above the heatmaps display the gene
(black bar), transcription start (arrow), the relative location of the CpG
islands (CGI) and the analyzed amplicons (MA). Dotplots show average
methylation per amplicon of AML patients and of healthy granulocytes
(HG). Median methylation of a sample group (median methylation in
AML samples for PRDM16, 5%; for ROBO3, 7.5%; and for CXCL14, 17.3%)
is depicted by a black bar. Mann-Whitney U test was used to test for
differences between AML samples and healthy granulocytes/CD34+ cells
(*P < 0.05, **P <0.01, ***P < 0.001).
Additional file 10: A table showing overrepresented motifs in
hypermethylated CGIs of the preleukemic stage. The table shows the
results of de novo motif search of the preleukemic hypermethylated CGIs
compared to whole genome background enrichment (47,511 target
sequences).
Additional file 11: A table showing the overlap of preleukemic
hypermethylated CGIs (covered by at least two hypermethylated
probes) with genomic coordinates of PU.1 ChIP-Seq data. The table
shows chromosomal location of the respective gene (columns A to D) and
the gene name (column E) of overlapping preleukemic hypermethylated
CGIs and publicly available ChIP-Seq data (selected by the more stringent
criteria of two hypermethylated probes covering the gene).
Additional file 12: A figure depicting the quantitative
determination of DNA methylation in PU.1 target genes. (A-C)
Heatmaps (left) and dotplots (right) of amplicons from Hes6 (A), Tal1 (B)
and Itpka (C) in PU.1-wt animals and different disease stages are shown.
Heatmaps display single CpG units (columns) of different PU.1-wt and
PU.1-kd animals. Differently colored bars to the right of the heatmaps
indicate preleukemic (P, black), early leukemic (EL, blue), late leukemic (LL,
red), and PU.1-wt (W, green). In vitro methylated standard DNA (0%, 20%,
40%, 60%, 80% and 100% DNA methylation; S, grey) served as control.
Methylation values range from 0% (light green) to 100% (dark blue).
Schemes above the heatmaps display the gene (black bar), transcription
start (arrow), the PU.1 ChIP peak (PU1), the relative location of the CpG
islands (CGI) and the analyzed amplicons (MA). Dotplots show average
methylation per amplicon of PU.1-wt animals and the different disease
stages. Median methylation of a sample group is depicted by a black bar.
Mann-Whitney U test was used to test for differences between PU.1-wt and
stages and within the different stages (*P < 0.05, **P <0.01, ***P < 0.001).
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